绥美凯国内上市后的价格

What is the price of Suimeikai (Doteta Abalami Tablets, Inbec) after it is launched in China? Let’s find out today. On January 20, 2018, GlaxoSmithKline China (GSK China) announced that its single-tablet compound preparation Suimeike (Dolutea, Inbec) (chemical name: Dolutea, Inbec) was officially launched in mainland China.

Suimeikai (Domitabalamid Tablets, Inbec) is currently priced at 2,880$/month in the Chinese market. If patients cannot afford the domestic price of Inbec, they can choose to purchase the original drug Inbec (Dolutea, Inbec) which is available in India. The price is relatively cheap. Inbec, a box of 30 tablets produced by the Indian company Emcure, is priced at about RMB 1,000. It is the most cost-effective version of Inbec in the world.

There are generally two most reliable ways to buy genuine Indian Suimeike (Dolutea Paramid Tablets, Inbec): First, if you are able, the patient himself goes to a well-known hospital in India and goes to the corresponding pharmacy to get the medicine according to the prescription issued by the attending doctor. This can ensure formal channels for obtaining medicines from the source. The second way is to find a professional overseas medical service organization in China (such as Medical Travel). Medical Travel has cooperation with foreign pharmaceutical companies and can help you buy genuine Indian Suimeike (Dolute Abalami Tablets, Inbec).

In 2016, GSK launched the integrase DTG (Inbec) in China. This therapeutic agent has the advantages of small drug dosage, resistance to drug resistance, and low probability of drug side effects. This time, Inbec (Inbec) uses DTG, an integrase inhibitor, as the core drug, and combines it with abacavir and lamivudine as a treatment plan. It is made into a single-tablet treatment and promoted, making the core drug a great progress in HAART treatment. In addition, Suimeike (Domitabalamid Tablets, Inbec) treatment can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and effectively improving the patients' quality of life and work.